Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ocugen, Inc.OCGN · Entity 5550 | Director | June 11, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ocugen, Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2036-06-11 | Direct | 170,100 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 170,100 · Balance 170,100 F1: The option vests upon the earlier of (a) June 11, 2027 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests upon the earlier of (a) June 11, 2027 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 20:35 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantStock Option (Right to Buy) · Derivative | 170,100 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001104659-26-074078 · tm2617964-5_4seq1.xml · derivative · entry 1 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,100 Underlying: Common Stock · 170,100 shares Expires 2036-06-11 F1 · derivative.exercise_date: The option vests upon the earlier of (a) June 11, 2027 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 21:18 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOption (Right to Buy) · Derivative | 151,316 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001062993-25-011272 · form4.xml · derivative · entry 1 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,316 Underlying: Common Stock · 151,316 shares Expires 2035-06-05 F1 · derivative.exercise_date: The option vests upon the earlier of (a) June 5, 2026 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 20:10 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOption (Right to Buy) · Derivative | 66,929 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001062993-24-013297 · form4.xml · derivative · entry 1 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,929 Underlying: Common Stock · 66,929 shares Expires 2034-06-28 F1 · derivative.exercise_date: The option vests upon the earlier of (a) June 28, 2025 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 09, 2023 Filed Jun 9, 2023 21:27 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOption (Right to Buy) · Derivative | 112,205 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001104659-23-070025 · tm2318370-4_4seq1.xml · derivative · entry 1 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,205 Underlying: Common Stock · 112,205 shares Expires 2033-06-09 F1 · derivative.exercise_date: The option vests upon the earlier of (a) June 9, 2024 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 00:57 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOption (Right to Buy) · Derivative | 140,091 | $0.00 Strike: $2.49 | $0.00 |
DisclosureSEC source: 0001062993-22-014511 · form4.xml · derivative · entry 1 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,091 Underlying: Common Stock · 140,091 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option vests upon the earlier of (a) June 7, 2023 and (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| December 16, 2021 Filed Dec 18, 2021 02:22 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOption (Right to Buy) · Derivative | 16,335 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0001104659-21-151341 · tm2135818-3_4seq1.xml · derivative · entry 1 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,335 Underlying: Common Stock · 16,335 shares Expires 2031-12-16 F1 · derivative.exercise_date: The option vests monthly in equal installments over three years commencing on January 16, 2022, subject to continued service with Ocugen, Inc. on the applicable vesting dates. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 23:38 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 25,000 | $16.01 | $400,250.00 |
DisclosureSEC source: 0001891015-21-000011 · edgar.xml · nonDerivative · entry 2 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: Kompella LLC Disclosed balance after: 154,416 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 23:38 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 25,000 | $14.05 | $351,250.00 |
DisclosureSEC source: 0001891015-21-000011 · edgar.xml · nonDerivative · entry 1 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: Kompella LLC Disclosed balance after: 179,416 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 26, 2021 Filed Oct 27, 2021 20:55 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 25,000 | $12.05 | $301,250.00 |
DisclosureSEC source: 0001192482-21-000746 · edgar.xml · nonDerivative · entry 2 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: Kompella LLC Disclosed balance after: 204,416 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 25, 2021 Filed Oct 27, 2021 20:55 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 46,371 | $9.08 | $421,048.68 |
DisclosureSEC source: 0001192482-21-000746 · edgar.xml · nonDerivative · entry 1 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: Kompella LLC Disclosed balance after: 229,416 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.00 to $9.36. The Reporting Person undertakes to provide to Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 21, 2021 Filed Oct 22, 2021 23:58 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 1,898 | $9.01 | $17,100.98 |
DisclosureSEC source: 0001882178-21-000034 · edgar.xml · nonDerivative · entry 1 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: Kompella LLC Disclosed balance after: 275,787 F1 · shares: This sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.00 to $9.02. The Reporting Person undertakes to provide to Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 20, 2021 Filed Oct 20, 2021 22:57 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 1,731 | $9.02 | $15,613.62 |
DisclosureSEC source: 0001879785-21-000010 · edgar.xml · nonDerivative · entry 2 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: Kompella LLC Disclosed balance after: 277,685 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.00 to $9.03. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 18, 2021 Filed Oct 20, 2021 22:57 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 200,000 | $8.41 | $1,682,000.00 |
DisclosureSEC source: 0001879785-21-000010 · edgar.xml · nonDerivative · entry 1 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: Kompella LLC Disclosed balance after: 279,416 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $8.12 to $8.81. The Reporting Person undertakes to provide to Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 30, 2021 Filed Jul 30, 2021 21:28 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOption (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.83 | $0.00 |
DisclosureSEC source: 0001192482-21-000639 · edgar.xml · derivative · entry 4 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,000 Underlying: Common Stock · 10,000 shares Expires 2031-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, initially representing a right to purchase a total of 126,000 shares, vests and becomes exercisable in equal monthly installments over three years commencing on February 1, 2021, subject to continued service with the Company on the applicable vesting dates. Read SEC document |
| July 30, 2021 Filed Jul 30, 2021 21:28 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 10,000 | $6.81 | $68,072.00 |
DisclosureSEC source: 0001192482-21-000639 · edgar.xml · nonDerivative · entry 2 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,674 F1 · shares: This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.76 to $6.85. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 30, 2021 Filed Jul 30, 2021 21:28 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 10,000 | $1.83 | $18,300.00 |
DisclosureSEC source: 0001192482-21-000639 · edgar.xml · nonDerivative · entry 1 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 560,674 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 25, 2021 Filed Jun 25, 2021 20:17 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOption (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.83 | $0.00 |
DisclosureSEC source: 0001192482-21-000575 · edgar.xml · derivative · entry 4 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,000 Underlying: Common Stock · 10,000 shares Expires 2031-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 17,500 shares under the option are exercisable. The option, initially representing a right to purchase a total of 126,000 shares, vests and becomes exercisable in equal monthly installments over three years commencing on February 2, 2021, subject to continued service with the Company on the applicable vesting dates. Read SEC document |
| June 25, 2021 Filed Jun 25, 2021 20:17 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 10,000 | $8.13 | $81,345.00 |
DisclosureSEC source: 0001192482-21-000575 · edgar.xml · nonDerivative · entry 2 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,674 F1 · shares: This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.07 to $8.20. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 25, 2021 Filed Jun 25, 2021 20:17 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 10,000 | $1.83 | $18,300.00 |
DisclosureSEC source: 0001192482-21-000575 · edgar.xml · nonDerivative · entry 1 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 560,674 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 10:10 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOption (right to buy) · Derivative | 7,191 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0001192482-21-000472 · edgar.xml · derivative · entry 4 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,191 shares Expires 2025-08-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, initially representing a right to purchase a total of 7,191 shares, vested and became exercisable on September 27, 2019. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 10:10 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 7,191 | $8.82 | $63,417.43 |
DisclosureSEC source: 0001192482-21-000472 · edgar.xml · nonDerivative · entry 2 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,674 F1 · shares: This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.81 to $8.86. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 10:10 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 7,191 | $1.88 | $13,519.08 |
DisclosureSEC source: 0001192482-21-000472 · edgar.xml · nonDerivative · entry 1 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 557,865 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2021 Filed May 4, 2021 01:05 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 25,000 | $16.02 | $400,500.00 |
DisclosureSEC source: 0001192482-21-000393 · edgar.xml · nonDerivative · entry 4 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,674 F1 · shares: This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| May 03, 2021 Filed May 4, 2021 01:05 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 25,000 | $14.00 | $350,000.00 |
DisclosureSEC source: 0001192482-21-000393 · edgar.xml · nonDerivative · entry 3 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 575,674 F1 · shares: This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 30, 2021 Filed May 4, 2021 01:05 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOption (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001192482-21-000393 · edgar.xml · derivative · entry 6 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 20,000 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 24,000 shares under the option are exercisable. The option, initially representing a right to purchase a total of 54,000 shares, vests and becomes exercisable over three years commencing on February 2, 2020, subject to continued service with the Company on the applicable vesting dates. Read SEC document |
| April 30, 2021 Filed May 4, 2021 01:05 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 20,000 | $11.56 | $231,200.00 |
DisclosureSEC source: 0001192482-21-000393 · edgar.xml · nonDerivative · entry 2 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,674 F1 · shares: This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $11.43 to $11.70. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 30, 2021 Filed May 4, 2021 01:05 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 20,000 | $0.51 | $10,200.00 |
DisclosureSEC source: 0001192482-21-000393 · edgar.xml · nonDerivative · entry 1 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 620,674 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 26, 2021 Filed Apr 28, 2021 22:52 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 350,000 | $11.70 | $4,095,000.00 |
DisclosureSEC source: 0001192482-21-000371 · edgar.xml · nonDerivative · entry 1 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,674 F1 · shares: This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.8300 to $12.5400. Read SEC document |
| January 01, 2021 Filed Jan 4, 2021 22:49 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOption (Right to Buy) · Derivative | 126,000 | $0.00 Strike: $1.83 | $0.00 |
DisclosureSEC source: 0001192482-21-000024 · edgar.xml · derivative · entry 1 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,000 Underlying: Common Stock · 126,000 shares Expires 2031-01-01 F1 · derivative.exercise_date: The option vests monthly in equal installments over three years commencing on February 1, 2021, subject to continued service with the Company on the applicable vesting dates. Read SEC document |
| January 02, 2020 Filed Jan 4, 2020 01:19 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOptions (Right to Buy) · Derivative | 54,000 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001192482-20-000018 · edgar.xml · derivative · entry 1 Kompella Uday · CIK 0001791821 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Stock · 54,000 shares Expires 2030-01-02 F1 · derivative.exercise_date: The options vest monthly in equal installments over three years commencing on February 2, 2020, subject to continued service with the Company on the applicable vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.